What is Zacks Research’s Estimate for EW FY2024 Earnings?

Edwards Lifesciences Co. (NYSE:EW) – Stock analysts at Zacks Research increased their FY2024 earnings per share (EPS) estimates for shares of Edwards Lifesciences in a research report issued on Tuesday, January 7th. Zacks Research analyst R. Department now expects that the medical research company will earn $2.58 per share for the year, up from their prior forecast of $2.57. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.56 per share. Zacks Research also issued estimates for Edwards Lifesciences’ Q4 2024 earnings at $0.55 EPS, Q2 2026 earnings at $0.67 EPS, Q3 2026 earnings at $0.71 EPS, Q4 2026 earnings at $0.72 EPS and FY2026 earnings at $2.76 EPS.

Other analysts also recently issued reports about the company. Piper Sandler lowered their price target on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Daiwa America downgraded Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 30th. Jefferies Financial Group downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating and lowered their price target for the company from $85.00 to $70.00 in a report on Wednesday, September 18th. Canaccord Genuity Group increased their price target on Edwards Lifesciences from $63.00 to $68.00 and gave the company a “hold” rating in a report on Thursday, December 5th. Finally, Royal Bank of Canada increased their price target on Edwards Lifesciences from $80.00 to $85.00 and gave the company an “outperform” rating in a report on Thursday, December 5th. Sixteen equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, Edwards Lifesciences has a consensus rating of “Hold” and a consensus price target of $79.40.

Edwards Lifesciences Stock Down 1.0 %

Shares of NYSE EW opened at $73.41 on Friday. Edwards Lifesciences has a 12-month low of $58.93 and a 12-month high of $96.12. The company has a market cap of $43.30 billion, a P/E ratio of 10.59, a P/E/G ratio of 3.61 and a beta of 1.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The stock has a fifty day moving average price of $71.64 and a 200 day moving average price of $72.06.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting analysts’ consensus estimates of $0.67. The business had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.59 EPS.

Hedge Funds Weigh In On Edwards Lifesciences

Large investors have recently bought and sold shares of the business. Nordea Investment Management AB lifted its holdings in Edwards Lifesciences by 34.6% in the fourth quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock worth $301,355,000 after acquiring an additional 1,043,484 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Edwards Lifesciences by 9.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 478,418 shares of the medical research company’s stock valued at $31,571,000 after purchasing an additional 40,348 shares during the period. AIA Group Ltd increased its stake in shares of Edwards Lifesciences by 91.7% in the third quarter. AIA Group Ltd now owns 749,524 shares of the medical research company’s stock valued at $49,461,000 after purchasing an additional 358,556 shares during the period. RiverPark Advisors LLC increased its stake in shares of Edwards Lifesciences by 58.1% in the third quarter. RiverPark Advisors LLC now owns 20,639 shares of the medical research company’s stock valued at $1,362,000 after purchasing an additional 7,583 shares during the period. Finally, Banque Cantonale Vaudoise increased its stake in shares of Edwards Lifesciences by 46.9% in the third quarter. Banque Cantonale Vaudoise now owns 81,111 shares of the medical research company’s stock valued at $5,353,000 after purchasing an additional 25,886 shares during the period. Institutional investors own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the transaction, the insider now owns 198,526 shares of the company’s stock, valued at $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total transaction of $347,550.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,262,521.36. This represents a 9.63 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 37,500 shares of company stock valued at $2,508,350. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.